Head-To-Head Analysis: Immatics (NASDAQ:IMTX) and Novonesis A/S (OTC:NVZMY)

Immatics (NASDAQ:IMTX) and Novonesis A/S (OTC:NVZMY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Volatility and Risk

Immatics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Novonesis A/S has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Valuation & Earnings

This table compares Immatics and Novonesis A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$155.84 million	2.68	-$104.98 million	$0.14	25.00
Novonesis A/S	$2.60 billion	10.98	$439.08 million	$1.58	38.55

Novonesis A/S has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Novonesis A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Immatics and Novonesis A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immatics	-47.94%	-15.90%	-9.38%
Novonesis A/S	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and recommmendations for Immatics and Novonesis A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	0	0	4	1	3.20
Novonesis A/S	1	0	0	0	1.00

Immatics presently has a consensus price target of $16.67, suggesting a potential upside of 376.19%. Given Immatics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Immatics is more favorable than Novonesis A/S.

Institutional and Insider Ownership

64.4% of Immatics shares are owned by institutional investors. Comparatively, 0.0% of Novonesis A/S shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Novonesis A/S beats Immatics on 9 of the 15 factors compared between the two stocks.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

About Novonesis A/S

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novonesis A/S was founded in 1925 and is based in Bagsvaerd, Denmark.